Zidesamtinib reported clinically meaningful activity in advanced ROS1-positive NSCLC with results from the global Phase I/II ARROS-1 trial. In treatment-naive, TKI-naive patients, the study reported a 94% response rate for the investigational agent. ROS1-rearranged NSCLC remains a genomically defined subtype where next-generation ROS1 inhibitors can compete by improving response depth, intracranial activity, and tolerability profiles compared with existing options. The “TKI-naive” framing also makes the efficacy signal particularly relevant for first-line positioning. Further evaluation will hinge on duration of response, progression-free survival, and safety—especially as the program advances dose optimization and expands cohorts.